Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03673124 · ClinicalTrials.gov registry record · Phase 2
Ribociclib and Letrozole Treatment in Ovarian Cancer
A Phase 2 study of Low Grade Serous Carcinoma, sponsored by Gynecologic Oncology Group.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT03673124 is a Phase 2 study of Low Grade Serous Carcinoma that is active but no longer recruiting, run by Gynecologic Oncology Group. The registered enrollment target is 51 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT03673124, a Phase 2 study of Low Grade Serous Carcinoma, is active but no longer recruiting, sponsored by Gynecologic Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Ribociclib
Study Locations (20)
Florida
- UF Heath - Gainesville
- Moffitt Cancer Center - Tampa
New Jersey
- Hackensack University Medical Center - Hackensack
- The Valley Hospital Inc. - Ridgewood
New Mexico
- New Mexico Cancer Care Alliance/University of New Mexico Comprehensive Cancer Center - Albuquerque
- Southwest Gynecologic Oncology Associates - Albuquerque
Ohio
- Miami Valley Hospital - Centerville
- The Ohio State Comprehensive Cancer Center - Columbus
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
- Oklahoma Cancer Care Specialists and Research Institute , LLC - Tulsa
Pennsylvania
- Western Pennsylvania Hospital/West Penn Hospital - Pittsburgh
- Abington Memorial Hospital - Willow Grove
California
- University of California, San Francisco - San Francisco
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03673124
The ClinicalTrials.gov registry entry for NCT03673124 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low Grade Serous Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Letrozole is the first listed.
NCT03673124 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, New Jersey, New Mexico.
Frequently Asked Questions
What is clinical trial NCT03673124 about?
NCT03673124 is a clinical study titled "Ribociclib and Letrozole Treatment in Ovarian Cancer". The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
What is the current status of trial NCT03673124?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2019-05-20. Estimated completion is 2026-12-31.
What conditions does trial NCT03673124 study?
This clinical trial studies the following conditions: Low Grade Serous Carcinoma.
What interventions are being tested in trial NCT03673124?
The interventions under investigation include: Letrozole (DRUG), Ribociclib (DRUG).
Who is sponsoring clinical trial NCT03673124?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03673124 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.